ANNUAL REPORT 2012 - TiGenix

7.5. SCIENTIFIC ADVISORY BOARD
AND CLINICAL ADVISORS
7.7.2. Shares and warrants held
by executive management
TiGenix SAU has appointed and closely works
with two scientific advisory boards for the
clinical development of the Cx601 and Cx611
programs :
- Gastroenterology advisory board : This
board is assisting the clinical development
of Cx601. The board is coordinated by Dr.
Julian Panés (Spain) and is integrated by Dr.
Jean-Frédéric Colombel (France), Dr. Walter
Reinisch (Austria), Dr. Gert Van Assche
(Belgium), Dr. Silvio Danese (Italy) and Dr.
Daniel Baumgart (Germany).
Please refer to section 13.7.7.
7.7.3. TiGenix Stock option plan
TiGenix created several warrants within the
context of stock option plans for employees,
consultants or directors of the Company, as
well as to persons who in the scope of their
professional activity have made themselves
useful to the Company.
For a description of the different stock option
plans of TiGenix, see section 5.6.
- Rheumatology advisory board : This board
is assisting the clinical development of
Cx611. The board is coordinated by Dr.
José María Alvaro-Gracia (Spain) and
is integrated by Dr. Victor Fernández-
Taboada (Spain), Dr. Federico Díaz-
González (Spain), Dr. Jesús Honorato
(Spain), Dr. Peter C. Taylor (UK) and Dr.
Georg A. Schett (Germany).
7.6. REMUNERATION REPORT
Please refer to section 13.7.7.
7.7. SHARES AND WARRANTS HELD
BY DIRECTORS AND EXECUTIVE
MANAGEMENT
7.7.1. Shares and warrants held
by independent and other
non-executive directors
Please refer to section 13.7.7.
7.7.4. TiGenix SAU Equity Based
Incentive Plans
7.7.4.1. Summary of the Equity Based
Incentive Plans
Prior to the contribution of all shares of TiGenix
SAU (previously : Cellerix SA) to the Company
on May 3, 2011 (the “Contribution”),
TiGenix SAU had created two Equity Based
Incentive Plans (“EBIPs”). The completion of
the Contribution on May 3, 2011 triggered
certain consequences outlined below
which affect both EBIPs (section 7.7.4.2). A
summary overview of some of the conditions
of both EBIPs is given below. Note (24) to the
consolidated financial statements, part of
Section 11.5.4 contains a numerical summary
of the options granted and outstanding as of
December 31, 2012.
EBIP 2008
An EBIP for the directors, managers and
employees of TiGenix SAU was approved at
the shareholders’ annual general meeting
of TiGenix SAU held on November 22, 2007,
95